TABLE 1.
Characteristics of a cohort of human immunodeficiency virus (HIV)‐infected adults with immune reconstitution inflammatory syndrome‐associated lymphoma (2000–2019).
| Characteristics | Number of patients, total N = 27 |
|---|---|
| ECOG 0 or 1, n (%) | 21 (78) |
| Median age (years) | 42 (range 25–62 years) |
| Males, n (%) | 23 (85) |
| Time between diagnosis of HIV and initiation of cART, n (%) | |
| <1 year | 19 (70.3) |
| 1–5 years | 4 (14.8) |
| 6–15 years | 4 (14.8) |
| Time between initiation of cART and diagnosis of lymphoma, n (%) | |
| < 3 months | 11 (47) |
| 3–6 months | 16 (59.3) |
| Histological type of lymphoma (%) | |
| Non‐Hodgkin lymphoma | 96.2 |
| Diffuse large B‐cell lymphoma | 61.5 |
| Burkitt lymphoma | 33.4 |
| Plasmablastic lymphoma | 2.55 |
| T‐cell lymphoma | 2.55 |
| Hodgkin lymphoma | 3.7 |
| Ki67 ≥90%, n (%) | 21 (77) |
| Advanced stage, n (%) | 20 (74) |
| Extranodal involvement, n (%) | 15 (55) |
| Liver | 3 (20) |
| Bone marrow | 4 (26) |
| Central nervous system | 3 (20) |
| Gastrointestinal tract | 3 (20) |
| Lung | 2 (14) |
| Chemotherapy protocol, n (%) | |
| CHOP | 11 (40.7) |
| R‐CHOP | 2 (7.4) |
| ABVD | 1 (3.7) |
| CHOEP | 4 (14.8) |
| DA‐EPOCH | 3 (11.1) |
| Hyper‐CVAD | 5 (18.5) |
| Codox‐M‐IVAC | 1 (3.7) |
| Nadir CD4+ T lymphocyte count prior to initiation of cART, n (%) | |
| <200 cells/mm3 | 21 (77.7) |
| 200–350 cells/mm3 | 2 (7.4) |
| >350 cells/mm3 | 4 (14.8) |
| Nadir CD4+ T lymphocyte count at diagnosis of lymphoma, n (%) | |
| <200 cells/mm3 | 16 (59.2) |
| 200–350 cells/mm3 | 6 (22.2) |
| >350 cells/mm3 | 5 (18.5) |
| Detectable viral load at diagnosis of lymphoma, n (%) | |
| <500 copies/mL | 16 (59.3) |
| 500–4999 copies/mL | 3 (11.1) |
| 5000–49,000 copies/mL | 5 (18.5) |
| >50,000 copies/mL | 3 (11.1) |
| cART at the moment of the diagnosis of lymphoma, n (%) | |
| Protease inhibitor | 1 (3.7) |
| NNRTI | 6 (22.2) |
| NRTI | 19 (70.3) |
| Other | 1 (3.7) |
| Co‐infection with hepatitis B/C | None |
| Primary refractory, n (%) | 4 (14.8) |
| Mean progression‐free survival (months) | 67.8 |
| Mean overall survival (months) | 77.6 |
| Mortality, n (%) | 6 (22.4) |
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; cART, combined antiretroviral therapy; CHOEP, cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CODOX‐M‐IVAC, cyclophosphamide, vincristine, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, high‐dose cytarabine; DA‐EPOCH, dose‐adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin; ECOG, Eastern Cooperative Oncology Group; Hyper‐CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high‐dose cytarabine and methotrexate; NNRTI, non‐nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.